Abstract：
UNASSIGNED: Recent interest in the potential therapeutic effects of psychedelics has led to investigations into their influence on molecular signaling pathways within the brain.
UNASSIGNED: Integrated review and analysis of different studies in this field.
UNASSIGNED: A systematic search was conducted across international databases including Embase, Scopus, Web of Science, and PubMed from inception to 9 July 2023. Eligibility criteria encompassed published and peer-reviewed studies evaluating changes in brain-derived neurotrophic factor (BDNF) levels after psychedelic consumption.
UNASSIGNED: A total of nine studies were included in our study. The meta-analysis demonstrated significantly higher BDNF levels in psychedelic consumers compared to healthy controls, with a pooled standardized mean difference of 0.26 (95% CI: 0.10-0.42, I2 = 38.51%, p < 0.001). Leave-one-out analysis indicated robustness in results upon removal of individual psychedelics. No significant publication bias was observed. The results highlight the potential influence of psychedelics on neuroplasticity by altering BDNF levels.
UNASSIGNED: More precisely, the documented rise in BDNF levels indicates a neurobiological mechanism by which psychedelics could enhance synaptic plasticity and foster the growth of neurons. Given the limited data available on this topic, the conclusions remain uncertain. Consequently, we highly recommend additional research with more extensive sample sizes to yield more reliable evidence in this field.
UNASSIGNED: Integrated review and analysis of different studies in this field.
UNASSIGNED: A systematic search was conducted across international databases including Embase, Scopus, Web of Science, and PubMed from inception to 9 July 2023. Eligibility criteria encompassed published and peer-reviewed studies evaluating changes in brain-derived neurotrophic factor (BDNF) levels after psychedelic consumption.
UNASSIGNED: A total of nine studies were included in our study. The meta-analysis demonstrated significantly higher BDNF levels in psychedelic consumers compared to healthy controls, with a pooled standardized mean difference of 0.26 (95% CI: 0.10-0.42, I2 = 38.51%, p < 0.001). Leave-one-out analysis indicated robustness in results upon removal of individual psychedelics. No significant publication bias was observed. The results highlight the potential influence of psychedelics on neuroplasticity by altering BDNF levels.
UNASSIGNED: More precisely, the documented rise in BDNF levels indicates a neurobiological mechanism by which psychedelics could enhance synaptic plasticity and foster the growth of neurons. Given the limited data available on this topic, the conclusions remain uncertain. Consequently, we highly recommend additional research with more extensive sample sizes to yield more reliable evidence in this field.
摘要：
■最近对迷幻药的潜在治疗作用的兴趣导致对其对脑内分子信号通路的影响的研究。
■对该领域不同研究的综合回顾和分析。
■在包括Embase在内的国际数据库中进行了系统搜索，Scopus,WebofScience,和PubMed从成立到2023年7月9日。资格标准包括已发表和同行评审的研究，这些研究评估了迷幻药食用后脑源性神经营养因子（BDNF）水平的变化。
■本研究共纳入9项研究。荟萃分析表明，与健康对照组相比，迷幻药消费者的BDNF水平明显更高，合并的标准化平均差为0.26(95%CI：0.10-0.42，I2=38.51%，p<0.001)。留一法分析表明，去除个体迷幻药后，结果具有稳健性。没有观察到显著的发表偏倚。结果强调了迷幻药通过改变BDNF水平对神经可塑性的潜在影响。
■更准确地说，有记录的BDNF水平升高表明迷幻药可以增强突触可塑性并促进神经元生长的神经生物学机制。鉴于有关此主题的可用数据有限，结论仍然不确定。因此,我们强烈建议更多的研究更广泛的样本量，以在这一领域产生更可靠的证据。
■对该领域不同研究的综合回顾和分析。
■在包括Embase在内的国际数据库中进行了系统搜索，Scopus,WebofScience,和PubMed从成立到2023年7月9日。资格标准包括已发表和同行评审的研究，这些研究评估了迷幻药食用后脑源性神经营养因子（BDNF）水平的变化。
■本研究共纳入9项研究。荟萃分析表明，与健康对照组相比，迷幻药消费者的BDNF水平明显更高，合并的标准化平均差为0.26(95%CI：0.10-0.42，I2=38.51%，p<0.001)。留一法分析表明，去除个体迷幻药后，结果具有稳健性。没有观察到显著的发表偏倚。结果强调了迷幻药通过改变BDNF水平对神经可塑性的潜在影响。
■更准确地说，有记录的BDNF水平升高表明迷幻药可以增强突触可塑性并促进神经元生长的神经生物学机制。鉴于有关此主题的可用数据有限，结论仍然不确定。因此,我们强烈建议更多的研究更广泛的样本量，以在这一领域产生更可靠的证据。
